Product category:
Nucleic acid sequencing and synthesis
News Release from: Applied Biosystems | Subject: Expression Array System
Edited by the Laboratorytalk Editorial
Team on 29 May 2006
Defining genome-wide events in leukaemia
Researchers at IHES and IRI use Expression Array System to understand gene regulatory events that are involved in the development of acute promyelocytic leukaemia on a genome-wide scale
Researchers at the Institut des Hautes Etudes Scientifiques and the Institut de Recherches Interdisciplinaires in France are using the Applied Biosystems Expression Array System to understand gene regulatory events that are involved in the development of acute promyelocytic leukaemia on a genome-wide scale Arndt Benecke, head of the systems epigenomics group, explained: "Using the 1700 chemiluminescent microarray analyzer and TaqMan gene expression assays, we are looking at samples from leukaemia patients to define multidimensional gene signatures
This article was originally published on Laboratorytalk on 14 Apr 2004 at 8.00am (UK)
Related stories
Worldwide availability of expression array system
Test site customers report that system can detect a greater number of genes with higher sensitivity and specificity than other microarray technologies
Analysing heart disease with array system
Dutch researchers use Expression Array System to identify genes that may predispose towards atherosclerosis, and validate them using TaqMan gene expression assays
"We are combining those studies with other microarray technologies, such as chromatin immunoprecipitation (ChIP)-on-chip, and translating the experimental results into probability maps using different computer algorithms.
"We then superimpose these probability maps onto the genomic sequence and develop methodology for analysing these data, using covariance and correlation coefficients, in order to make predictions concerning regulatory events.
"We chose the expression array system largely because of its wide gene coverage and the System's high sensitivity was also important.
"For most of the probes there are TaqMan assays available that have already been optimised, and this saves us lots of time in the downstream validation steps.
"Eventually we hope that our approach will allow sets of several potential pharmaceutical targets to be identified simultaneously for multifactorial diseases.
"This has never really been successfully established, but it is something that we are working towards.".
• Applied Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
